A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-418 in Healthy Female Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs TAK 418 (Primary)
- Indications Inborn genetic disorders
- Focus Adverse reactions
- Sponsors Takeda
- 03 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2018 Status changed from not yet recruiting to recruiting.
- 20 Apr 2018 New trial record